LABDDirexion Daily S&P Biotech Bear 3X Shares
Seeks daily investment results of 300% of the inverse performance of the Index.
By Direxion Funds · Launched 2015
Annual Cost
1.07%
#5,550 of 6,040 · expensive
Fund Size
$81M
#3,278 of 6,040 · mid-size
Return (1Y)
-85.4%
Track Record
11 years
#1,290 of 6,040 · established
Performance
Total-return NAV · USDGrowth of $10,000
$2,878-71.2%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaStrategy
Inverse
Index tracked
S&P Biotechnology Select Industry Index
Holdings
By weightConcentration
synthetic exposure — holdings shown are derivatives collateral, not the fund's positions
GOLDMAN FINANCIAL
45.3%
DREYFUS GOVERNMENT CASH MANAGE
44.6%
GOLDMAN SACHS LIQ ES FD A
14.7%
DREYFUS
5.7%
N/A
1.1%
N/A
-0.1%
N/A
-0.8%
N/A
-1.0%
N/A
-1.2%
N/A
-1.8%
Asset allocation
Cash
114.8%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
83.4%High
Year-on-year price swings
Max drawdown
-100.0%Severe
Worst peak-to-trough loss
Sharpe (3Y)
-0.83Below average
Sortino (3Y)
-1.13Moderate downside risk
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks daily investment results of 300% of the inverse performance of the Index.
- Strategy
- Invests primarily in financial instruments, including swap agreements and futures contracts, to provide 3X daily inverse exposure to the biotechnology sub-industry Index. Concentrates investments in U.S.-based companies with a float-adjusted market capitalization above $300 million, aiming for daily rebalancing to achieve its investment objective.
- Inception date
- May 28, 2015
- Fund family
- Direxion Funds
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save LABD to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18